| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JAC/DKR466 |
| P8608 | Fatcat ID | release_73rzfglve5c3fe6o7ze5cpehmi |
| P698 | PubMed publication ID | 22096042 |
| P5875 | ResearchGate publication ID | 51811092 |
| P50 | author | Matthew E. Falagas | Q87082633 |
| Drosos E. Karageorgopoulos | Q54297342 | ||
| P2093 | author name string | Rui Wang | |
| Xu-Hong Yu | |||
| P2860 | cites work | Zelkovamycin, a new cyclic peptide antibiotic from Streptomyces sp. K96-0670. II. Structure elucidation | Q74636885 |
| MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli | Q24671787 | ||
| Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate | Q24676974 | ||
| Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli | Q27641769 | ||
| Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin | Q27734363 | ||
| The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa | Q28492495 | ||
| Identification of a novel UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) from Vibrio fischeri that confers high fosfomycin resistance in Escherichia coli | Q33416937 | ||
| Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections | Q33564290 | ||
| Mutation frequencies and antibiotic resistance | Q33945503 | ||
| Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes | Q33962732 | ||
| Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. | Q34096605 | ||
| Mutator bacteria as a risk factor in treatment of infectious diseases | Q34113782 | ||
| Minimizing potential resistance: a population dynamics view. | Q34347875 | ||
| Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections | Q34421301 | ||
| Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily | Q34482492 | ||
| Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models | Q35212401 | ||
| Why fosfomycin trometamol as first line therapy for uncomplicated UTI? | Q35550901 | ||
| Biological costs and mechanisms of fosfomycin resistance in Escherichia coli | Q35685710 | ||
| Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation | Q35893671 | ||
| Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections | Q37614630 | ||
| Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials | Q37768581 | ||
| Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. | Q37860758 | ||
| Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes | Q37894694 | ||
| Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. | Q37915817 | ||
| Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. | Q39473127 | ||
| High frequency of mutator strains among human uropathogenic Escherichia coli isolates. | Q39694657 | ||
| Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria | Q39832506 | ||
| Fosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains | Q39990097 | ||
| Effect of Fosfomycin on the Fecal Microflora of Man | Q40745009 | ||
| Bactericidal activity of tinidazole. An in vitro comparison of the effects of tinidazole and metronidazole against Bacteroides fragilis and other Anaerobic bacteria | Q40745019 | ||
| Sulfadiazine-Trimethoprim Combination in the Treatment of Urinary Tract Infections | Q40809409 | ||
| Bacteriological evaluation of fosfomycin in clinical studies | Q40885291 | ||
| In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development | Q42012459 | ||
| Detection of hypermutable Escherichia coli strains in a collection of clinical isolates by the fosfomycin-rifampin disk method. | Q42370976 | ||
| Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa | Q42375984 | ||
| Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis | Q42550334 | ||
| Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli | Q42705384 | ||
| Novel Fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996. | Q42729873 | ||
| Extracellular concentrations of fosfomycin in lung tissue of septic patients | Q43130327 | ||
| Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. | Q43131134 | ||
| Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli | Q43195414 | ||
| CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. | Q43293884 | ||
| Fosfomycin-resistance plasmids determine an intracellular modification of fosfomycin | Q43423840 | ||
| Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance | Q44144059 | ||
| Fosfomycin in the treatment of gynecological infections | Q44359736 | ||
| Effect of enzyme I of the bacterial phosphoenolpyruvate : sugar phosphotransferase system (PTS) on virulence in a murine model | Q44569232 | ||
| Fosmidomycin Resistance in Adenylate Cyclase Deficient (cya) Mutants ofEscherichia coli | Q44603208 | ||
| In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance | Q44607486 | ||
| Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of an Italian multicenter survey | Q44624204 | ||
| Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance | Q44676765 | ||
| Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis | Q44697825 | ||
| Treatment of chronic suppurated otitis with fosfomycin | Q45050517 | ||
| Introducing fosfomycin for surgical prophylaxis--emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures | Q45105226 | ||
| Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. | Q45949360 | ||
| Changes in the antimicrobial susceptibility of Escherichia coli isolates from nosocomial versus community-acquired urinary tract infections | Q46434638 | ||
| Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis | Q46505710 | ||
| Antibiotic resistance transformation in community-acquired urinary infections | Q46560038 | ||
| Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study | Q46635982 | ||
| Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. | Q46795441 | ||
| A theoretical and experimental analysis of bacterial growth in the bladder | Q52426375 | ||
| Fosfomycin in acute bronchopneumopathies | Q54198445 | ||
| Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/Co-trimoxazole | Q54282481 | ||
| Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. | Q54372713 | ||
| Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia. | Q54423105 | ||
| [Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?] | Q54454211 | ||
| Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. | Q54458242 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Gram-negative bacteria | Q632006 |
| antimicrobial resistance | Q63391344 | ||
| P304 | page(s) | 255-268 | |
| P577 | publication date | 2011-11-16 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens | |
| P478 | volume | 67 |
| Q21131125 | "Stormy waters ahead": global emergence of carbapenemases |
| Q48274337 | A Molecular Docking and Dynamics Approach to Screen Potent Inhibitors Against Fosfomycin Resistant Enzyme in Clinical Klebsiella pneumoniae |
| Q54089542 | Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study. |
| Q53693483 | Adherence to International Guidelines for the Treatment of Uncomplicated Urinary Tract Infections in Lebanon. |
| Q90422727 | Analysis of urine-specific antibiograms from veterans to guide empiric therapy for suspected urinary tract infection |
| Q39249188 | Antimicrobial treatment of serious gram-negative infections in newborns |
| Q47143645 | Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis |
| Q46493036 | Appropriate Targets for Antibacterial Drugs |
| Q40789035 | Carbapenem- and Colistin-Resistant Enterobacter cloacae from Delta, Colorado, in 2015. |
| Q37154718 | Carbapenem-Resistant Enterobacteriaceae Infections in Children |
| Q34320945 | Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes |
| Q93088195 | Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy |
| Q35966554 | Cefepime shows good efficacy and no antibiotic resistance in pneumonia caused by Serratia marcescens and Proteus mirabilis - an observational study. |
| Q41639665 | Characterization of fosA5, a new plasmid-mediated fosfomycin resistance gene in Escherichia coli |
| Q36290521 | Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. |
| Q40697349 | Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. |
| Q38161570 | Combating multidrug-resistant Gram-negative bacterial infections |
| Q58756032 | Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli |
| Q90625351 | Cost-effectiveness of antibiotic treatment of uncomplicated urinary tract infection in women: a comparison of four antibiotics |
| Q90381422 | Evaluation of Immunocompetent Urinary Tract Infected Balb/C Mouse Model For the Study of Antibiotic Resistance Development Using Escherichia Coli CFT073 Infection |
| Q39425303 | Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study |
| Q90446935 | Evaluation of in vitro susceptibility of fosfomycin among Enterobacteriaceae isolates from urine cultures: A study from Puducherry |
| Q93149909 | Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae |
| Q34709726 | F33: A-: B-, IncHI2/ST3, and IncI1/ST71 plasmids drive the dissemination of fosA3 and bla CTX-M-55/-14/-65 in Escherichia coli from chickens in China |
| Q36675246 | Fosfomycin |
| Q90189782 | Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics |
| Q33732529 | Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012. |
| Q92299756 | Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial |
| Q38208281 | Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists |
| Q64917427 | Fosfomycin in the pediatric setting: Evidence and potential indications. |
| Q51801490 | Fosfomycin resistance in Acinetobacter baumannii is mediated by efflux through a major facilitator superfamily (MFS) transporter-AbaF. |
| Q33703401 | Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany |
| Q38160759 | Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria |
| Q35278325 | Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial |
| Q37001229 | Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains |
| Q26745740 | Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis |
| Q39071416 | Fosfomycin: Mechanism and Resistance |
| Q48380261 | Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli. |
| Q91344662 | Functional and structural basis of E. coli enolase inhibition by SF2312: a mimic of the carbanion intermediate |
| Q28354064 | Genome-Wide Identification of Antimicrobial Intrinsic Resistance Determinants in Staphylococcus aureus |
| Q37544647 | In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study. |
| Q35076855 | In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates |
| Q41388208 | In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa |
| Q92237003 | In vitro and in vivo activity of ciprofloxacin/fosfomycin combination therapy against ciprofloxacin-resistant Shigella flexneri isolates |
| Q90070133 | In vivo acquisition of fosfomycin resistance in Escherichia coli by fosA transmission from commensal flora |
| Q40049542 | Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections |
| Q90477681 | Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada |
| Q40333130 | Mechanism of Reduced Susceptibility to Fosfomycin in Escherichia coli Clinical Isolates |
| Q89181871 | Menacing Emergence of Fosfomycin Resistance Among Klebsiella pneumoniae Carbapenemase-2-Producing K. pneumoniae Driven by Prior Use in Critically Ill Patients |
| Q36490822 | Molecular Basis for Resistance Against Phosphonate Antibiotics and Herbicides |
| Q64939222 | Multidrug-Resistant Organisms: Considerations in Antibiotic Selection and Administration. |
| Q36761826 | Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. |
| Q40962124 | Multidrug-resistant bacteria in Germany. The impact of sources outside healthcare facilities |
| Q42272359 | Multidrug-resistant gram-negative bacteria infections in solid organ transplantation |
| Q40422166 | Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges. |
| Q64886188 | New microbiological aspects of fosfomycin. |
| Q61801651 | Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems |
| Q40632842 | Obtaining i.v. fosfomycin through an expanded-access protocol |
| Q36160749 | Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study |
| Q37538644 | Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy |
| Q46286730 | Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae |
| Q35960788 | Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance |
| Q51734361 | Pharmacokinetics and Pharmacodynamics of Fosfomycin and its Activity against ESBL-, Plasmid-mediated AmpC- and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model. |
| Q92553297 | Prevalence and characteristics of Livestock-Associated Methicillin-Resistant Staphylococcus aureus (LA-MRSA) isolated from chicken meat in the province of Quebec, Canada |
| Q34921154 | Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions |
| Q26859841 | Resistance to antibiotics targeted to the bacterial cell wall |
| Q41908390 | Role of the CpxAR two-component signal transduction system in control of fosfomycin resistance and carbon substrate uptake |
| Q43085392 | Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae |
| Q38325217 | Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. |
| Q89571328 | Synthesis, Spectroscopic Characterization, and In Vitro Antibacterial Evaluation of Novel Functionalized Sulfamidocarbonyloxyphosphonates |
| Q38833839 | Tackling antimicrobial resistance in lower urinary tract infections: treatment options |
| Q38689344 | The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria |
| Q33686940 | The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies |
| Q91844976 | The inhibitory mechanism of aurintricarboxylic acid targeting serine/threonine phosphatase Stp1 in Staphylococcus aureus: insights from molecular dynamics simulations |
| Q92311262 | The role of fosfomycin in osteoarticular infection |
| Q52695014 | Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. |
| Q38185648 | Treatment of multidrug-resistant Gram-negative infections in children |
| Q36683661 | Uncomplicated Urinary Tract Infections and Antibiotic Resistance-Epidemiological and Mechanistic Aspects |
| Q92500177 | Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis |
| Q40499211 | Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study |
| Q40406138 | Whole-Genome Analysis of Antimicrobial-Resistant and Extraintestinal Pathogenic Escherichia coli in River Water. |
Search more.